Companies › Immunis
1 active drug program in 1 registered trial: 1 Phase 2; Metabolic and endocrine; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IMM01-STEM Allogeneic cell-free secretome product derived from partially differentiated human stem ce | – | Phase 2 | Muscle Performance | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06600581 | IMM01-STEM | Phase 2 | Muscle Performance | Metabolic and endocrine | Dec 2026 |
No annotated target.
–
AB Biotics Estar Medical dba Medical Technologies Wellizen Australia Yong Zhao, MD, PhD Spur Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.